GlassScriptPhysician profile
Alan Hawxby
NPI 1225047145
$2,333.42
in general payments reported to CMS, 2019-2025
25 companies · $70.25 in 2025
The $70.25 reported for 2025 was less than what a typical Transplant Surgery provider received nationally (typical 2025 total: $423).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $368 · 2020: $297 · 2022: $488 · 2023: $266 · 2024: $844 · 2025: $70.25.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,180.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $505.34 | 2022-2024 | Signia |
| Veloxis Pharmaceuticals, INC. | $306.86 | 2019-2025 | Envarsus |
| Abbvie INC. | $195.02 | 2019-2024 | |
| Mallinckrodt Hospital Products INC. | $190.45 | 2022-2024 | Terlivaz |
| Boston Scientific Corporation | $128.00 | 2024 | Therasphere Y90 Glass Microspheres 10 Gbq |
| Gilead Sciences, INC. | $127.62 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $123.39 | 2020 | |
| Sanofi-Aventis U.S. LLC | $121.60 | 2023 | |
| Ethicon US, LLC | $94.44 | 2024 | Echelon Circular |
| Agiliti Surgical, INC. | $77.34 | 2020 | |
| Intercept Pharmaceuticals, INC. | $73.23 | 2019-2024 | |
| Paragonix Technologies, INC. | $67.89 | 2024 | Liverguard, Sherpapak, Pancreaspak |
| Merck Sharp & Dohme LLC | $40.95 | 2023-2024 | Prevymis |
| Baxter Healthcare | $33.62 | 2023 | Tisseel |
| Pacira Pharmaceuticals Incorporated | $27.94 | 2024 | Exparel |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $26.85 | 2019 | |
| Acera Surgical, INC. | $26.54 | 2024 | Restrata Wound Matrix |
| Innovation Technologies INC | $25.84 | 2024 | Irrisept |
| Otsuka America Pharmaceutical, INC. | $25.17 | 2025 | Jynarque |
| Calliditas Therapeutics US INC. | $21.55 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.77 | 2023 | Livtencity |
| Mimedx Group, INC. | $19.74 | 2024 | |
| Kci USA, INC. | $19.71 | 2023 | Prevena |
| Novartis Pharmaceuticals Corporation | $18.98 | 2024 | |
| Alexion Pharmaceuticals, INC. | $14.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Hawxby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.